Inovio Pharmaceuticals is trading 10.05% down at $1.70, with no verified company-specific announcement on November 3 explaining the decline. - FDA approval of VOCERYQ was reported November 2 and accompanied a sharp prior-session rally, but evidence does not establish it as the cause of this session’s pullback. - The supplied sector context shows biotech rising, which does not explain the stock’s opposite-direction move. - Inovio Pharmaceuticals is scheduled to report third-quarter results November 10; that date is not a confirmed catalyst for today’s decline.